A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B‐induced decompensated liver cirrhosis

A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord... IntroductionThough liver owns a considerable inherent regenerate ability, continuous and chronic injury leads to the onset of hepatic cirrhosis. Various stimuli such as hepatitis virus, alcohol, drugs, and autoimmune assault by hepatic cells can touch off hepatocyte apoptosis, damage the endothelial barrier, accumulate the inflammatory cells, and activate hepatic stellate cells. In China, chronic hepatitis B virus (HBV) infection is the major factor of liver cirrhosis (LC). LC generally progresses irreversibly into a decompensated phase, which is featured by a sequence of clinical manifestations, including ascites, variceal hemorrhage, and hepatic encephalopathy. Apparently, hepatic cirrhosis is easy to progress to liver failure, and the condition of patient in hepatic failure with accompanying LC is more serious, and the prognosis is worse. Currently, the most effective therapy for end‐stage LC is liver transplantation. However, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical expense.While originally isolated from bone marrow, mesenchymal stem cells (MSCs) are widely distributed in the postnatal organism and adult organs or tissues, which are multipotent stromal cells with self‐renewing potential characterized by their capacity to differentiate into the cells of the mesodermal and ectodermal lineage. Furthermore, a large quantity of experiments http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gastroenterology and Hepatology Wiley

A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B‐induced decompensated liver cirrhosis

Loading next page...
 
/lp/wiley/a-study-about-immunomodulatory-effect-and-efficacy-and-prognosis-of-VcW4QSEFUr
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
ISSN
0815-9319
eISSN
1440-1746
D.O.I.
10.1111/jgh.14081
Publisher site
See Article on Publisher Site

Abstract

IntroductionThough liver owns a considerable inherent regenerate ability, continuous and chronic injury leads to the onset of hepatic cirrhosis. Various stimuli such as hepatitis virus, alcohol, drugs, and autoimmune assault by hepatic cells can touch off hepatocyte apoptosis, damage the endothelial barrier, accumulate the inflammatory cells, and activate hepatic stellate cells. In China, chronic hepatitis B virus (HBV) infection is the major factor of liver cirrhosis (LC). LC generally progresses irreversibly into a decompensated phase, which is featured by a sequence of clinical manifestations, including ascites, variceal hemorrhage, and hepatic encephalopathy. Apparently, hepatic cirrhosis is easy to progress to liver failure, and the condition of patient in hepatic failure with accompanying LC is more serious, and the prognosis is worse. Currently, the most effective therapy for end‐stage LC is liver transplantation. However, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical expense.While originally isolated from bone marrow, mesenchymal stem cells (MSCs) are widely distributed in the postnatal organism and adult organs or tissues, which are multipotent stromal cells with self‐renewing potential characterized by their capacity to differentiate into the cells of the mesodermal and ectodermal lineage. Furthermore, a large quantity of experiments

Journal

Journal of Gastroenterology and HepatologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off